CLOs on the Move

Spirovant

www.spirovant.com

 
Spirovant is a gene therapy company focused on changing the course of cystic fibrosis and other respiratory diseases. The company`s current investigational gene therapy technologies are designed to overcome the historical barriers that have prevented effective genetic treatments for cystic fibrosis. Spirovant`s lead programs are in development for cystic fibrosis. Spirovant is a wholly owned subsidiary of Sumitovant Biopharma Ltd., which is itself a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Spirovant is located in Philadelphia, PA.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.spirovant.com
  • 3675 Market Street Suite 200
    Philadelphia, PA USA 19104
  • Phone: 267.244.8206

Executives

Name Title Contact Details

Similar Companies

Hoffmann-La Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. prescription drug unit of the Roche Group, a leading research-based health care enterprise that ranks among the world's leaders in pharmaceuticals, diagnostics and vitamins. Roche

Kymanox

Kymanox is a professional services organization with a focus on project delivery. Our team of experts provide guide you and your project.

Peplin Limited(Now LeoPharma)

Peplin Limited(Now LeoPharma) is a Emeryville, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BICO

We are industry-leading experts in Bio Convergence. By combining the power of biology, engineering and computer science, we create the future of health. We extend the boundaries of what`s possible to give people better and healthier lives. Products from the BICO Group are trusted by more than 2,00 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 1800 publications. BICO is creating the future of health. Visit bico.com to learn more. BICO is listed on the Nasdaq Stockholm Main Market under BICO.

Jnana

Jnana was founded by leading academic scientists, drug developers and investors to develop medicines that transform the lives of patients by targeting the cell`s metabolic gates.